Verapamil Benefits Chronic Rhinosinusitis With Nasal Polyps

Share this content:
Verapamil Benefits Chronic Rhinosinusitis With Nasal Polyps
Verapamil Benefits Chronic Rhinosinusitis With Nasal Polyps

THURSDAY, Jan. 26, 2017 (HealthDay News) -- For patients with chronic rhinosinusitis with nasal polyps (CRSwNP), the first-generation inhibitor of epithelial P-glycoprotein (P-gp; an efflux pump that is overexpressed in CRSwNP), verapamil hydrochloride (HCl), is associated with improvement in outcome measures, according to a letter to the editor study published online Jan. 23 in the Journal of Allergy and Clinical Immunology.

Marcel M. Miyake, M.D., from Harvard Medical School in Boston, and colleagues conducted a randomized placebo-controlled trial comparing oral verapamil HCl to placebo over eight weeks. Patients were followed up at weeks two, four, and eight. Eighteen patients completed the study: 10 from the verapamil group and eight from the placebo group.

The researchers found that from baseline to week eight, the least squares mean change in the validated disease-specific 22-item Sinonasal Outcome Test was −27.3 and 0.4 in the verapamil and placebo groups, respectively, resulting in a final difference between the groups of −27.7 (P = 0.01). The final least squares mean between-group difference in visual analogue scale score was −37.97 (P = 0.001). There was a significant difference favoring the verapamil group in the Lund-Mackay computed tomography score (absolute mean difference, −5.20; P = 0.02). The verapamil group also had a significant reduction in total Lund-Kennedy endoscopic score at week four (least mean squares difference of −2.8 between the groups; P = 0.003).

"Our data demonstrate that low-dose verapamil monotherapy is well tolerated by patients, with [fewer] side effects and lower costs than those reported in previous studies using biologic agents," the authors write.

Several authors disclosed financial ties to medical technology companies; one author provided expert testimony on ENT-related cases, and has a patent for P-gp inhibition for chronic rhinosinusitis.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Saturday Is National Prescription Drug Take Back Day

Saturday Is National Prescription Drug Take Back Day

Unused medications can be dropped off at local collection sites between 10 a.m. and 2 p.m.

Multiple Myeloma Risk May Be Up for WTC-Exposed Firefighters

Multiple Myeloma Risk May Be Up for WTC-Exposed ...

And, cancer burden projected to be greater than expected for world trade center-exposed firefighters

Pros and Cons for E-Cigarettes As Aid to Smoking Cessation

Pros and Cons for E-Cigarettes As Aid to ...

Researchers present evidence supporting their use, and discuss the limits and hazards of use

is free, fast, and customized just for you!

Already a member?

Sign In Now »